News and communications

  1. Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial
  2. Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
  3. Ponatinib (Iclusig▼): reports of posterior reversible encephalopathy syndrome
  4. Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children
See all news and communications